KRAS and cancer: The genetically engineered mouse models expressing these oncogenic mutations result in constitutive activation of K-Ras, that regulates downstream signaling pathways involved in proliferation, migration, and metastasis of cancer cells (di Magliano and Logsdon, 2013).